- E-postbergithe.oftedal@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Jeg er utdannet molekylærbiolog og jobber innen immunogenetikk med fokus på endokrin autoimmun sykdom. Siden disputasen min i 2012 ved Universitetet i Bergen fortsatte jeg som post-Doc i samme gruppe og hadde ett års forskningsopphold hos Professor Hamish Scott ved University of Adelaide hvor jeg jobbet med genetikk. Jeg ble så tildelt et mobilitetsstipend fra Norges Forskningsråd og jobbet to år i gruppen til Professor Georg Holländer ved University of Oxford hvor jeg arbeidet med karakterisering av utvikling av T-celler i tymus. Siden 2019 har jeg vært ansatt som seniorforsker ved KG Jebsen-senteret for autoimmune sykdommer, og jeg ble nylig tildelt det prestisjetunge Excellence Emerging Investigator-stipendet fra Novo Nordic-stiftelsen. Mitt langsiktige mål er å karakterisere genetiske og molekylære mekanismer i det adaptive immunsystemet som er avgjørende for utviklingen av tolerante T-celler og B-celler. Videre vil jeg kombinerer denne kunnskapen i multivariante sykdomsmodeller for bedre å forutsi autoimmunt vevsdestruksjon. I tillegg ønsker jeg å utvide mitt internasjonale nettverk med mulighet for langsiktige samarbeid.
2024 (upcoming):
Invited speaker at the 21st Biennial Meeting of the European Society for Immunodeficiencies (ESID), Marseille, France, 16.-19. October, 2024
2022:
Invited speaker at European Congress of Endocrinology (ECE) 2022, 21–24 May 2022 in Milan Italy,
Invited speaer at the 20th Biennial Meeting of the European Society for Immunodeficiencies (ESID), Gothenburg, Sweden, 12-15 October, 2022.
2016:
Invited speaker, 12th Annual Symposium on Primary Immunodeficiency Diseases, California, USA
Selected speaker at the 43rd Scandinavian Society for Immunology meeting, Turku, Finland.
2015
Selected speaker at The Thymus Meeting 2015, Venice, Italy
Invited speaker at the Norwegian Immunological Society annual meeting
- (2024). Regulatory T cells in autoimmune primary adrenal insufficiency. Clinical and Experimental Immunology. 47-57.
- (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 18 sider.
- (2023). Th17 Cells: Orchestrators of Mucosal Inflammation and Potential Therapeutic Targets. Critical Reviews in Immunology. 25-52.
- (2023). Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1. FEBS Letters. 1261-1274.
- (2023). Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes. iScience. 17 sider.
- (2023). Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy. Diabetes. 59-70.
- (2023). A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation.
- (2022). Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. Journal of Autoimmunity. 1-?.
- (2022). Extrathymic expression of Aire controls the induction of effective T<inf>H</inf>17 cell-mediated immune response to Candida albicans. Nature Immunology. 1098-1108.
- (2021). Transcriptional changes in regulatory T cells from patients with autoimmune polyendocrine syndrome type 1 suggest functional impairment of lipid metabolism and gut homing. Frontiers in Immunology. 1-12.
- (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology (EJE). 607-615.
- (2021). The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function. Communications Biology.
- (2021). Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine (JEM).
- (2021). GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nature Communications. 1-14.
- (2019). Identification and characterization of rare Toll-like receptor 3 variants in patients with autoimmune Addison’s disease. Journal of translational autoimmunity.
- (2019). Coexistence of congenital adrenal hyperplasia and autoimmune Addison's disease. Frontiers in Endocrinology. 1-5.
- (2018). Oral microbiota in autoimmune polyendocrine syndrome type 1. Journal of Oral Microbiology. 1-10.
- (2018). 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I. Clinical and Experimental Immunology. 1-5.
- (2017). T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ. Journal of Autoimmunity. 24-33.
- (2017). Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I. Autoimmunity. 211-222.
- (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. Journal of Pediatric Endocrinology & Metabolism (JPEM). 3546-3556.
- (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
- (2016). Antibodies against NALP5 and it's role in hypoparathyroidism in autoimmune polyglandular syndrome type 1. Problemy Endokrinologii. 25-30.
- (2016). A variant in the BACH2 gene is associated with susceptibility to autoimmune addison's disease in humans. Journal of Clinical Endocrinology and Metabolism (JCEM). 3865-3869.
- (2016). A longitudinal follow-up of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism (JCEM). 2975-2983.
- (2015). Revealing missing human protein isoforms based on Ab initio prediction, RNA-seq and proteomics. Scientific Reports.
- (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 1185-1196.
- (2015). 8q13.1-q13.2 deletion associated with inferior cerebellar vermian hypoplasia and digital anomalies: A new syndrome? Pediatric Neurology. 230-234.e1.
- (2014). Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. Journal of Immunology. 3880-3890.
- (2014). ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism (JCEM). E1784-E1792.
- (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 220-227.
- (2013). Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. Journal of Clinical Immunology. 1341-1348.
- (2012). Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. Journal of Clinical Immunology. 230-237.
- (2011). Measuring autoantibodies against IL-17F and IL-22 in Autoimmune Polyendocrine Syndrome Type I by radioligand binding assay using fusion proteins. Scandinavian Journal of Immunology. 327-333.
- (2010). Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in autoimmune polyendocrine syndrome type I. Scandinavian Journal of Immunology. 459-467.
- (2008). Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clinical Immunology. 163-169.
- (2008). AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes and Immunity. 130-136.
- (2005). Ligand-dependent protein interactions of the estrogen receptors using the yeast two-hybrid system. Annals of the New York Academy of Sciences. 420-425.
- (2005). Exploring protein-protein interactions between ligand activated transcription factors using the yeast two-hybrid system.
- (2019). Exploring and redefining Autoimmune polyendocrine syndrome type 1.
- (2012). Autoimmune polyendocrine syndrome type I –novel diagnostic assays and immune regulation.
- (2019). The Natural History of APS1. 7 sider.
- (2019). Aire Mutations and Autoimmune Diseases. 24 sider.
- (2013). Dominant Inheritance in Autoimmune Endocrine Syndrome Type 1. Scandinavian Journal of Immunology. 306-307.
- (2012). Deviant expression of defensins in sera and saliva of patients with autoimmune polyendocrine syndrome type I. Immunology. 211-212.
- (2010). Nucleoporin 62, a Novel Autoantigen in Patients with Autoimmune Polyendocrine Syndrome Type I (APS I). Scandinavian Journal of Immunology. 493-494.
- (2013). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with APS-1.
- (2023). Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Frontiers in Endocrinology.
- (2021). B cells and autoantibodies in aire deficiency. Biomedicines. 1-15.
- (2020). The prospects of single-cell analysis in autoimmunity. Scandinavian Journal of Immunology. 1-15.
- (2020). New ERA of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology. 1-23.
- (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology. 8-15.
Se fullstendig oversikt over publikasjoner i CRIStin.
Utvalgte publikasjoner:
2023:
36. A partial form of AIRE deficiency underlies a mild form of Autoimmune Polyendocrine Syndrome Type 1.
Oftedal BE, Berger AH, Bruserud Ø, Goldfarb Y, Sulen A, Breivik L, Hellesen A, Ben-Dor S, Haffner-Krausz R , Knappskog PM, Johansson S, Wolff ASB, Bratland E, Abramson J, Husebye ES.
J Clin Invest. 2023 Nov 1;133(21):e169704. doi: 10.1172/JCI169704.
35. Regulatory T cells in autoimmune primary adrenal insufficiency.
Sjøgren T, Bjune JI, Husebye ES, Oftedal BE, Wolff ASB.
Clin Exp Immunol. 2023 Aug 14: uxad087. doi: 10.1093/cei/uxad087. Online ahead of print.
34. Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies.
Wolff ASB, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES.
iScience. 2023 Jul 21;26(7):107084. doi: 10.1016/j.isci.2023.107084. Epub 2023 Jun 9.
33. Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes.
Oftedal BE, Assing K, Baris S, Safgren SL, Johansen IS, Jakobsen MA, Babovic-Vuksanovic D, Agre K, Klee EW, Majcic E, Ferré EMN, Schmitt MM, DiMaggio T, Rosen LB, Rahman MO, Chrysis D, Giannakopoulos A, Garcia MT, González-Granado LI, Stanley K, Galant-Swafford J, Suwannarat P, Meyts I, Lionakis MS, Husebye ES.
iScience. 2023 May 5;26(6):106818. doi: 10.1016/j.isci.2023.106818. eCollection 2023 Jun 16.
32. Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1.
Oftedal BE, Delaleu N, Dolan D, Meager A, Husebye ES, Wolff ASB.
FEBS Lett. 2023 Apr 13. doi: 10.1002/1873-3468.14625. Online ahead of print. PMID: 37052889
31. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL.
Diabetes. 2023 Jan 1;72(1):59-70. doi: 10.2337/db21-1172.PMID: 35709010
2022:
30. Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies.
Sjøgren T, Bratland E, Røyrvik EC, Grytaas MA, Benneche A, Knappskog PM, Kämpe O, Oftedal BE, Husebye ES, Wolff ASB.
J Autoimmun. 2022 Dec;133:102917. doi: 10.1016/j.jaut.2022.102917. Epub 2022 Sep 30. PMID: 36191466
29. Extrathymic expression of Aire modulates the induction of effective TH17 cell-mediated immune response to Candida albicans.
J Dobeš, O Ben-Nun, A Binyamin, L Stoler-Barak, BE Oftedal, Y Goldfarb, N Kadouri, Y Gruper, T Givony, I Zalayat, K Kováčová, H Böhmová, E Valter, Z Shulman, D Filipp, ES Husebye, J Abramson
Nat Immunol. 2022 Jul;23(7):1098-1108. doi: 10.1038/s41590-022-01247-6. Epub 2022 Jun 27.
PMID: 35761088
2021:
28. Transcriptional Changes in Regulatory T Cells from Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing.
Berger AH, Bratland E, Sjøgren T, Heimli M, Tyssedal T, Bruserud Ø, Johansson S, Husebye ES, Oftedal BE, Wolff ASB.
Front Immunol. 2021 Aug 30;12:722860. doi: 10.3389/fimmu.2021.722860. eCollection 2021.
27. Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation
Y. Goldfarb, T. Givony, N. Kadouri, J. Dobeš, C. Peligero-Cruz, I. Zalayat, G. Damari, B. Dassa, S. Ben-Dor, Y. Gruper, BE. Oftedal, E. Bratland, MM. Erichsen, A. Berger, A. Avin, S. Nevo, U. Haljasorg, Y. Kuperman, A. Ulman, R. Haffner-Krausz, Z. Porat, U. Atasoy, D. Leshkowitz, ES. Husebye, J. Abramson
J Exp Med. 2021 Nov 1;218(11):e20201076. doi: 10.1084/jem.20201076. Epub 2021 Sep 3.
26. The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function
BE Oftedal, S Maio, A Händel, MPJ White, D Howie, S Davis, N Prevot, IA Rota, ME Deadman, BM Kessler, R Fischer, NS Trede, E Sezgin, RM Maizels, GA Holländer
Nature Communications Biology, Commun. Biol 4, 681 (2021). https://doi.org/10.1038/s42003-021-02203-0
25. The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease
ASB Wolff, L Breivik, KO Hufthammer, MA Grytaas, E Bratland, ES Husebye, and BE Oftedal
The European Journal of Endocrinology, DOI: https://doi.org/10.1530/EJE-20-1268, Volume/Issue: Volume 184: Issue 4, Page Range: 607–615
24. GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.
D Eriksson, EC Røyrvik, M Aranda-Guillén, AH Berger, N Landegren, HA Alvarez, Å Hallgren, M Grytaas, S Ström, E Bratland, I Botusan, BE Oftedal ,…, S Johansson, O Kämpe, ES Husebye.
Nat Commun. 2021 Feb 11;12(1):959. doi: 10.1038/s41467-021-21015-8.
2019
23. Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.
Aslaksen S, Methlie P, Vigeland MD, Jøssang DE, Wolff AB, Sheng Y, Oftedal BE, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.
Front Endocrinol (Lausanne). 2019 Sep 27;10:648. doi: 10.3389/fendo.2019.00648.
22. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.
Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.
J Transl Autoimmun. 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.
2018
21. 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I.
Berglund A, Cleemann L, Oftedal BE, Holm K, Husebye ES, Gravholt CH.
Clin Exp Immunol. 2018 Oct 29. doi: 10.1111/cei.13231. PMID: 30372540
20.Oral microbiota in autoimmune polyendocrine syndrome type 1.
Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.
J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. PMID: 29503707
2017
19. Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune
Polyendocrine Syndrome Type 1.
Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.
Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.
PMID: 28919897
18. Salivary gland dysfunction in patients with autoimmune polyendocrine syndrome type I
BE Oftedal, M Cuida, MM Erichsen, M Tveiterås, A Østre, D Hammenfors, M Johnsson, K Kisand, R Klein, R Jonsson, ASB Wolff.
Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7.
PMID: 28686485
17. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1.
EM Orlova, LS Sozaeva, MA Kareva, BE Oftedal, ASB Wolff, L Breivik, EY Zakharova, O Kämpe, PM Knappskog, VA Peterkova, ES Husebye. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3546-3556. doi: 10.1210/jc.2017-00139. PMID: 28911151
16. T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ
Oftedal, B.E., Lundgren, B.A., Hamm, D., Finstermeier, K., Gan, P.Y., Holdsworth, S.R., Hahn, C.N., Schreiber, A.W., and Scott, H.S.
J Autoimmun. 2017 Mar 15. pii: S0896-8411(16)30344-4. doi: 10.1016/j.jaut.2017.03.002. [Epub ahead of print]. PMID: 28318808
2016
15. A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans
Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, Pearce SH, Mitchell AL.
J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869. Epub 2016 Sep 28. PMID: 27680876
14. A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1.
Bruserud Ø, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jørgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES.
J Clin Endocrinol Metab. 2016 Jun 2:jc20161821. [Epub ahead of print] PMID: 27253668
13. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases
BE Oftedal, A Hellesen, MM Erichsen, E Bratland, A Vardi, J Perheentupa, EH Kemp, T Fiskerstrand, MK Viken, AP Weetman, SJ Fleishman, S Banka, WG Newman, WAC Sewell, LS Sozaeva, T Zayats, K Haugarvoll, EM Orlova, J Haavik, S Johansson, PM Knappskog, K Løvås, ASB Wolff, J Abramson, Eystein S. Husebye
Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028
Impact factor: 24.1
2015
12. Revealing Missing Human Protein Isoforms Based on Ab Initio Prediction, RNA-seq and Proteomics
Hu, Z.-Q., Scott, H.S., Qin, G.-G., Zheng, G.-Y., Chu, X., Xie, L., Adelson, D.L., Oftedal, B.E.,
Venugopal, P., Babic, M., Hahn, C.N., Bing Zhang, B., Wang, X.-J., Nan Li, N., and Wei, C.-C.
SCIENTIFIC REPORTS 2015 Volume: 5, Article Number: 10940
11. 8q13.1-q13.2 Deletion Associated With Inferior Cerebellar Vermian Hypoplasia and Digital Anomalies: A New Syndrome?
Mordaunt D, Oftedal BE, Scott HS, Coates D, Barnett C
Pediatr Neurol. 2015 Feb;52(2):230-4.e1. doi: 10.1016/j.pediatrneurol.2014.09.002. PMID: 25693585
2014
10. Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen
Transcripts in Their Tumors.
Wolff ASB, Kärner J,Owe JF, Oftedal BE, Gilhus NE. Erichsen MM, Kämpe E,‖ Meager A, Peterson
P, Kisand K, Willcox N, Husebye ES
J Immunol. 2014 Oct 15;193(8):3880-90. doi: 10.4049/jimmunol.1401068. PMID: 25230752
9. ARMC5 MUTATIONS ARE COMMON IN FAMILIAL BILATERAL MACRONODULAR ADRENAL
HYPERPLASIA.
Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R,
Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB, Torpy DJ, Scott HS.
J Clin Endocrinol Metab. 2014 Jun 6:jc20141265. PMID:24905064
Citations: 36 (webofknowledge.com)
8. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.
Breivik L, Oftedal BE, Bøe Wolff AS, Bratland E, Orlova EM, Husebye ES.
Clin Immunol. 2014 Jul;153(1):220-7. doi: 10.1016/j.clim.2014.04.013. Epub 2014 May 2.
2013
7. Anti-Cytokine Autoantibodies Preceding Onset of Autoimmune Polyendocrine Syndrome Type I Features in Early Childhood.
Wolff AS, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BE, Kisand K, Oláh E, Meloni A, Myhre
AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A.
J Clin Immunol. 2013 Oct 26. [Epub ahead of print
2011
6. Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups.
Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS.
J Clin Immunol. 2011 Nov 30. [Epub ahead of print] PMID: 22127461
5. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins.
Oftedal BE, Kämpe O, Meager A, Ahlgren KM, Lobell A, Husebye ES, Wolff AS.
Scand J Immunol. 2011 Apr 28. [Epub ahead of print] PMID:21535082
2010
4. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in
autoimmune polyendocrine syndrome type I.
Wolff AS, Oftedal BE, Kisand K, Ersvaer E, Lima K, Husebye ES.
Scand J Immunol. 2010 Jun;71(6):459-67. PMID: 20500699
Citations: 24 (webofknowledge.com)
2008
3. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune
polyendocrine syndrome type I.
Oftedal BE, Wolff AS, Bratland E, Kämpe O, Perheentupa J, Myhre AG, Meager A, Purushothaman R, Ten S, Husebye ES.
Clin Immunol. 2008 Oct;129(1):163-9. Epub 2008 Aug 16.PMID: 18708298
2. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene
deletions contribute to APS I.
Bøe Wolff AS, Oftedal B, Johansson S, Bruland O, Løvås K, Meager A, Pedersen C, Husebye ES,
Knappskog PM.
Genes Immun. 2008 Mar;9(2):130-6. Epub 2008 Jan 17.PMID: 18200029
2022-2027 “21-Hydroxylase reactive B cells and their immunotherapeutic potential in autoimmune Addison’s disease”. Funded by the Novo Nordic Fundation. 10 000 000 DKK. Oftedal is the project leader.
2021-2024 “Will B-cell tell the tales? Autoimmune B cells in autoimmune Addison’s disease”. Funded by the Regional Health Authorities. 3 000 000 NOK, Oftedal is the project leader.
2017-2021 “KG Jebsen center for autoimmune disorders”. A national centre established in Bergen, where Oftedal is a principal investigator. Funded by KG Jebsen, 18 000 000.
2017-2020 “Identification of novel monogenic autoimmune syndromes”. Partners are Husebye, Bratland and Wolff. Funded by Norwegian Research Council, 4 000 000 NOK.
2016-2019 “New perspectives on regulation of peripheral tissue antigen expression within the thymus”. Oftedal is the project leader. Partners are Georg Holländer and Eystein Husebye. Funded by the Norwegian Research Council. 3 328 000 NOK
Normal 0 false false false EN-GB X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;}